Paige Mahaney C4 Therapeutics, Inc. (CCCC) insider trading activity

CCCC Quotes by TradingView

Paige Mahaney is Chief Scientific Officer of C4 Therapeutics, Inc.. Currently has a direct ownership of 99,356 shares of CCCC, which is worth approximately $245,409. The most recent transaction as insider was on Oct 28, 2025, when has been sold 5,644 shares (Common Stock) at a price of $2.58 per share, resulting in proceeds of $14,561. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 99.4K
5.38% 3M change
29.37% 12M change
Total Value Held $245,409

Paige Mahaney Transaction History

Date Transaction Value Shares Traded Shares Held Form
Oct 28 2025
SELL
Payment of exercise price or tax liability
$14,561 $2.58 p/Share
5,644 Reduced 5.38%
99,356 Common Stock
Oct 28 2025
BUY
Exercise of conversion of derivative security
-
19,200 Added 15.46%
105,000 Common Stock
Feb 14 2025
BUY
Grant, award, or other acquisition
-
28,200 Added 21.17%
105,000 Common Stock
Oct 28 2024
BUY
Grant, award, or other acquisition
-
76,800 Added 50.0%
76,800 Common Stock
PM

Paige Mahaney

Chief Scientific Officer
Watertown, MA

Track Institutional and Insider Activities on CCCC

Follow C4 Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CCCC shares.

Notify only if

Insider Trading

Get notified when an C4 Therapeutics, Inc. insider buys or sells CCCC shares.

Notify only if

News

Receive news related to C4 Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on CCCC